Use these to boost your biotech exposure

Biotechnology companies have been at the forefront of some of the most exciting developments in healthcare over the past two decades—and there are more developments in the pipeline. However, the high cost of product development, long lead times for product testing and regulatory approvals, and… Read More

Three riskier ETFs with recovery potential

The recent market downturn has been especially hard on riskier stocks—and all three of these ETFs are down considerably from their 2021 highs. But the best of the stocks these ETFs hold are at the forefront of innovative industries or segments that still have considerable… Read More